Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MIRACLE

Financiado

Cerrado

Integrated multi-angle research and training network to eradicate leukemia minim...

Integrated multi-angle research and training network to eradicate leukemia minimal residual disease An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemia (AML), which is generally a disease of the elderly, while acute lymphoid leukemia (ALL)... ver más

30/11/2028

STICHTING AMSTERDA...

Presupuesto desconocido

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-12-01

HORIZON-MSCA-2023-DN-01-01: MSCA Doctoral Networks 2023 Expected Outcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

STICHTING AMSTERDAM UMC

Lider

Proyectos interesantes

AltCheM

Medical Technol...

Data Science

2M€ Cerrado

MRDAML

Medical Technol...

Data Science

Cerrado

TREAT-NPM1-AML

Medical Technol...

Data Science

3M€ Cerrado

RESOLVE

Medical Technol...

Data Science

8M€ Cerrado

DECIDE

Medical Technol...

Data Science

3M€ Cerrado

CNS2023-145442

Medical Technol...

Oncology

189K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 47 meses Fecha Inicio: 2024-12-01
Fecha Fin: 2028-11-30

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemia (AML), which is generally a disease of the elderly, while acute lymphoid leukemia (ALL) is most prevalent in children. The biggest problem associated with leukemia treatment is persistence of residual therapy-resistant cancer cells, called minimal residual disease (MRD). MRD can latently persist in the patient for many months, and in response to unknown signals can reawaken and initiate a relapse, which is difficult to treat and responsible for the low survival rates of patients. Currently, knowledge on mechanisms responsible for persistence of MRD and initiation of leukemia relapse is lacking, making development of therapeutics eradicating MRD difficult and hampering improvement of patient cure rates. MIRACLE aims at eradication of MRD and development of clinically efficient treatment strategies that can deliver long-lasting benefit to patients by training a new generation of researchers.MIRACLE will elucidate the leukemia MRD landscape by integrating the knowledge on mechanisms driving persistence of MRD from different angles, and by the subsequent design of efficient and less toxic, novel targeted combination therapy with increased capacity to induce deep responses in patients. With its multidisciplinary team of scientists from academia and industry MIRACLE aims to educate a new generation of researchers optimally equipped to advance and accelerate development of novel therapeutics directed to MRD, and to progress effective treatments to the clinic. The researchers within MIRACLE will be trained to obtain a unique combination of skills in innovative high-tech technologies, advanced data analysis tools and artificial intelligence, organ-on-chip MRD models, and drug and immunotherapy testing, and will come with innovative ideas to advance future leukemia treatment by integration of several disciplines and data sources.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores